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ABSTRACT
CHARACTERIZATION OF ANTIBODIES FOR OSTEOPONTIN
FRAGMENTS IN RHEUMATOID ARTHRITIS
by Shadi Sharif
The pro-inflammatory cytokine osteopontin (OPN) is present in rheumatoid
arthritis (RA) synovial fluid. Osteopontin can be cleaved by thrombin (OPN-R) exposing
a cryptic a 4 pi / OC9P1 integrin-binding motif (SVVYGLR). The C-terminal arginine in
thrombin-cleaved OPN can be further cleaved by plasma carboxypeptidase B (CPB)
abrogating thrombin-cleaved OPN's binding to the integrins (OPN-L). Specificity of
antibodies against OPN-R and OPN-L were determined by Western blot and peptide
blocking studies. Epitope mapping of antibodies revealed Anti-OPN-R and Anti-OPN-L
recognize the bold amino acids from SVVYGLR and S W Y G L respectively. AntiOPN-R and Anti-OPN-L ELISA were developed with sensitivity of 0.6 ng/ml.
Significantly elevated OPN-R and OPN-L levels were detected from rheumatoid arthritis
synovial fluids compared to osteoarthritis (OA) and psoriatic arthritis (PsA).
Furthermore, preferential adherence of fibroblast-like synoviocytes from joints to OPN-R
rather than OPN-L, suggests thrombin-cleaved OPN may play a role in pathogenesis of
RA which in turn is being regulated by CPB.
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Introduction
Osteopontin is a highly glycosylated serine/threonine phosphoprotein found in
plasma and in extracellular matrix. It functions as a pro-inflammatory cytokine at sites of
inflammation and is also implicated in bone remodeling (1, 2). OPN is expressed by
many different cell types including macrophages, natural killer cells, and activated T
lymphocytes (3, 4, 5, 6).

Recently several groups have shown that there is local

production of OPN in human rheumatoid arthritic joints (7, 8, 9, 10).
Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune inflammatory
joint disease with complex pathophysiology. RA is characterized by the infiltration of
inflammatory cells into the joint space leading to invasive growth of synovial tissue
(pannus) and destruction of cartilage and bone (11). Recently, several independent
groups have suggested that osteopontin plays an essential role in RA (7, 12, 8).
Osteopontin contains an Arg-Gly-Asp (RGD) sequence (Fig. 1) that mediates its
binding to multiple integrins including ocvP3 (the vitronectin receptor) on the surface of
osteoclasts. It also contains a CD44-binding domain for bone matrix interactions
important in bone remodeling (13). OPN is an inflammatory cytokine that has been
shown to induce cell attachment (14) and chemotaxis (15) through RGD-dependent
interactions with different integrins including ocvPi, avP3, ocvPs, OC5P1, asPi (1, 2).
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FIGURE 1. Important features of human osteopontin.
Some features of human osteopontin, integrin binding motifs and receptor binding sites
are depicted. Thrombin cleavage site and the sequential plasma CPB cleavage sites are
indicated by arrows.

OPN also has an integrin-binding motif that is only exposed after its cleavage by
thrombin (Fig. 1 & Fig. 2). This cryptic motif is the short peptide sequence SVVYGLR
(in human OPN) and SLAYGLR (in mouse OPN) which interacts with a 4 pi (16, 17, 18)
and a 9 Pi integrins (19, 20). a4(3i otherwise known as VLA-4 or CD49d / CD29 is
expressed on the surface of lymphocytes and smooth muscle cells (16, 17, 18) while agf3i
is expressed on neutrophils, epithelial cells and smooth muscle cells (19, 20, 21).
According to both Bayless (17) and Green (18) the interactions of SVVYGLR (located
on the C-terminal end of the N-terminal thrombin-cleaved OPN fragment) with a4(3i and
agPi integrins are independent of the RGD motif.

2

FIGURE 2. Generation of OPN-R and OPN-L by sequential cleavage by thrombin and
plasma carboxypeptidase B.
The sequence of full-length human osteopontin near its thrombin cleavage site is
depicted. A, Treatment of OPN with thrombin (Factor Ha) results in generation of OPNR and C-terminal fragment. E) Plasma carboxypeptidase B (CPB) removes C-terminal
arginin from OPN-R to generate OPN-L.

Recently Yamamoto et al. demonstrated that the cryptic epitope of OPN
(SLAYGLR) has an essential role in a mouse model of rheumatoid arthritis (12). They
successfully demonstrated that a blocking antibody against the exposed cryptic epitope of
OPN in RA inhibited pannus proliferation and infiltration of inflammatory cells, in
addition to reducing bone erosions in vivo. This finding is direct evidence that in the
murine model of RA the thrombin-cleaved OPN plays an essential role in progression of
disease. The thrombin cleavage of OPN is depicted in Figure 2. The existence of
thrombin-cleaved OPN has also been detected in human rheumatoid arthritis synovial
fluids by Ohshima et al. using an indirect ELISA method (10). Ohshima et al. compared
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the binding of an antibody that recognizes intact and cleaved OPN to one that recognizes
full-length OPN only. Clearly, findings by both Yamamoto et al. and Ohshima et al.
suggest that thrombin-cleaved form of OPN is important in both human and murine
model of RA.
Plasma carboxypeptidase B (CPB), also called thrombin-activatable fibrinolysis
inhibitor or TAFI, can inactivate thrombin-cleaved OPN adhesion to Jurkat T cells by
removing the C-terminal arginine from the exposed SVVYGLR epitope (14). Cleavage
by CPB converts the thrombin-cleaved OPN (OPN-R) into the inactive des-arg form
(OPN-L) (Fig. 2). Both thrombin and CPB are generated locally within the joint space in
RA (22). Therefore, one may hypothesize that CPB regulates the inflammatory role of
thrombin-cleaved OPN in RA.
In order to investigate the specific inflammatory role of thrombin-cleaved OPN
(OPN-R) in RA and its regulation by CPB, I have characterized two antibodies and
determined their sensitivity and specificity for their respective antigens, OPN-R and
OPN-L. I have also developed specific sandwich ELISA for direct detection of OPN-R
and OPN-L from biological fluids, and investigated the levels of OPN-R and OPN-L in
rheumatoid arthritis in comparison to osteoarthritis (OA) and psoriatic arthritis (PsA).
Furthermore, to explore the functional role of OPN-R in RA, I have demonstrated that
fibroblast-like synoviocytes lining the inflamed joints of RA patients, which express 0C4
integrin, bind preferentially to OPN-R.
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Materials and Methods
Reagents
Human OPN Quantikine ELISA kit was purchased from R&D Systems
(Minneapolis, MN). Goat anti-rabbit HRP-labeled antibody conjugate was from Jackson
Immunological (West Grove, PA). Heteroblock was purchased from Omega Biologicals
(Bozeman, MT).

Human thrombin was obtained from Haematologic Technologies

(Essex Junction, VA), while CPB was from ACTICHROME CPB activity kit purchased
from American Diagnostica (Stamford, CT). The peptides SLAYGL, SWYGL and
SLAYGLR were synthesized by the peptide synthesis facility at Beckman Center,
Stanford University School of Medicine. For epitope mapping of antibodies, a series of
peptides were designed based on the immunogen sequences with introduction of alanine
in place of each amino acid (Table I). The peptides for Anti-OPN-R (CA1999) and antiOPN-L (CA1998) were synthesized at Elim Biopharmaceuticals Inc (Hayward, CA).

Table I. List of peptides used to map the epitope for Anti-OPN-R andAnti-OPN-L
Anti-OPN-R Peptides
Anti-OPN-L Peptides
RLGYALS (random peptide)
RLGYALS (random peptide)
SLAYGLR (Anti-OPN-R immunogen) SVVYGL (Anti-OPN-L immunogen)
SAAYGLR
SAVYGL
SLAYGLR
SVAYGL
SLAAGLR
SVVAGL
SLAYALR
SVVYAL
SLAYGAR
SVVYGA
SLAYGLA
SWYGL-NH2
SLAYGLR-NH2
To investigate significance of each amino acid within the immunogen sequence, alanine
was introduced in place of each amino acid (shown in blod), and affinities of the antibodies for
the mutated peptides were determined as discussed in text.
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Antibodies
The antibodies were generated at Berelex Laboratories Incorporated, and were
kindly donated to Dr. Lawrence Leung's Laboratory at Stanford School of Medicine,
where this research was conducted. Rabbits were immunized with short peptides from
the carboxyl termini of human VDTYDRGDSWYGLR (CA2001) for detection of
OPN-FL; human SVVYGLR (CA1997) and mouse SLAYGLR (CA1999) for detection
of OPN-R, and carboxyl termini of human SWYGL (CA1998), mouse SLAYGL
(CA2000) for detection of OPN-L (Table II).

Table II. List of antibodies and their respective immunogens
Antibody Name
Anti-OPN (CA2001)
Anti-OPN-R (CA1999)
Anti-OPN-L (CA1998)
CA1997

Immunogen
VDTYDRGDSWYGLR
SLAYGLR (Mouse)
SVVYGL (Human)
S WYGLR (Human)

Antigen
Human OPN-FL, OPN-R, OPN-L
Human & Mouse OPN-R
Human OPN-L
Failed to recognize OPN-R Specifically

Synovial fluid samples
Archived synovial fluid samples were kindly provided by Dr. Jason J. Song and
Dr. William H. Robinson. 26 rheumatoid arthritis, 18 osteoarthritis and 10 psoriatic
arthritis samples were analyzed. Samples were stored at -80°C until use.
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Human osteopontin purification from milk
OPN was purified from human milk (Mothers Milk Bank, San Jose, CA)
according to previously published procedure with minor modifications (17). One liter of
human milk pooled from several donors was incubated on ice to allow for separation of
the whey from the curd. The whey was then clarified from the curd by centrifuging at
23000 x g for 60 min at 4°C, and filtered through a 0.2uM filter unit. ImM benzamidine
and 2mM DTT were added and the clarified whey was batch adsorbed to Q-sepharose
resin (GE Healthcare, Pittsburgh, PA) for 2 h at 4°C. Following batch-adsorption, the
resin was washed with lOmM NaPhosphate pH 7.4, 0.2M NaCl, 2mM DTT, ImM
benzamidine and the protein was eluted using lOmM Na Phosphate pH 7.4, 1M NaCl,
2mM DTT, ImM benzamidine. The eluant was dialyzed in lOmM Na Phosphate pH 7.4,
4M NaCl, 2mM DTT, ImM benzamidine overnight at 4°C, and loaded onto a 5ml HiTrap
Phenyl Sepharose HP column (GE Healthcare, Pittsburgh, PA) at lml/min. Then, the
column was washed until OD280 plateaued to a baseline level and a linear gradient from
4M to 2M NaCl at 1 ml/min was used to elute the proteins. 1ml fractions were collected
and analyzed by SDS-page. Pure fractions were pooled and dialyzed against PBS pH 7.4.
Impure fractions were dialyzed against 4M salt and re-applied to the phenyl sepharose
column until purified. The purified protein was sent out to Stanford University Beckman
Center for mass spectroscopy analysis and was confirmed as osteopontin (Data not
shown).
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Thrombin-cleaved OPN and thrombin / CPB-cleaved OPN preparation
To generate OPN-R, lOjig of purified milk osteopontin was digested with lOOnM
of thrombin in presence of 20mM HEPES, ImM CaCl2 , 150mM NaCl, 0.1% PEGgooo,
pH 7.6 at 37°C. After 2, 5, 10, 20, 30, 40, 50, 60, 75 minutes of incubation with
thrombin, the reaction was stopped using 200nM of the thrombin inhibitor, PPACK (DPhe-Pro-Arg-chloromethyl ketone). 500ng of OPN from each time point was analyzed
by SDS-PAGE. 60 minutes was determined to be the ideal time for complete conversion
of OPN to OPN-R. To make OPN-L, the thrombin-cleaved OPN-R was treated with
lOOnM CPB for 1 h at room temperature. Due to thermal instability of CPB, further
treatment was not necessary for stopping the reaction. OPN-R and OPN-L were analyzed
by SDS-PAGE and Western blot to ensure complete cleavage of milk OPN and the
proteins were aliquoted and stored at -80°C for use as a standard in ELISA.

Specificity determination of antibodies to OPN-FL, OPN-R and OPN-L by
Western blot
2ug of each of the three forms of osteopontin (prepared as described above), were
incubated with ImM DTT and sample loading buffer (Invitrogen, Carlsbad, CA) at 90°C
for 15 min and were vortexed. Three identical 10% Nuvex polyacrylamide gel were
prepared. Per gel, 3 identical sets of protein ladder, lOOng of OPN-F1, OPN-R and OPNL were run using MOPS running buffer. The proteins were later transferred onto PVDF
membranes (BioRad, Hercules, CA).

Stained Precision Plus Protein Marker (BioRad,

Hercules, CA) was used to ensure complete transfer of proteins to PVDF membrane. The
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blots were incubated in blocking buffer consistent of 50mM Tris-HCL, 2mM CaCL2,
80mm NaCl, 5% w/v non-fat milk and 0.2% Niodent P40, pH 8.0. Each membrane was
cut into three pieces, so that each piece contained a stained protein ladder, lOOng of
OPN-F1, OPN-R, and OPN-L. Membranes were probed with 1 ug/ml of each of the
antibodies, Anti-OPN, Anti-OPN-R, and Anti-OPN-L (Table II) respectively for 1 h.
Goat anti-rabbit horse radish preoxidase-linked IgG (Jackson Immunological, West
Grove, PA) was used as secondary antibody at 1/15000 in blocking buffer for 40 min,
and developed using ECL reagents (GE Healthcare, Pittsburgh, PA).
In order to determine the specificity of Anti-OPN-R and Anti-OPN-L antibodirs,
after incubation with blocking buffer the two blots were each cut into three identical
pieces, each piece containing a protein ladder, lOOng of OPN-F1, OPN-R and OPN-L.
Antibodies were pre-incubated with their cognate and non-cognate peptides (SWYGL
and SLAYGLR) at a molar ratio of 1:50 for 2 h at room temperature before probing the
membranes. The first three blots from the same gel were incubated for 1 h with AntiOPN-R, 1:50 molar ratio of Anti-OPN-R to SLAYGLR (congnate peptide), and 1:50
molar ratio of Anti-OPN-R to SWYGL (non-cognate peptide) respectively. The second
set of blots from the same gel were incubated for 1 h with Anti-OPN-L, 1:50 molar ratio
of Anti-OPN-L to SWYGL (congnate peptide), and 1:50 molar ratio of Anti-OPN-L to
SLAYGLR (non-cognate peptide) respectively.

After incubation with the primary

antibodies blots were treated as described above.
Identical 10% Nuvex polyacrylamide gel with lug of each of the three forms of
OPN was run along with the Western blot gels and was stained with Bio-Safe Coomassie
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G250 Stain (BioRad, Hercules, CA) to not only prove purity of the purified proteins in
each lane, but also as positive control for the electrophoresis.

Development of sandwich ELISAfor detection of human OPN
To detect OPN-FL from biological samples, a commercial ELISA kit (R&D
Systems OPN Quantikine ELISA Kit) was used according to the manufacturer's
instructions. For detection of OPN-R and OPN-L, the commercial R&D Systems OPN
antibody was used to capture, and Anti-OPN-R and Anti-OPN-L antibodies were used for
detection respectively. Various concentrations of the three forms of OPN ranging from
0.625ng/ml to 50ng/ml were incubated in the antibody-coated wells for 2 h at room
temperature. Wells were washed three times with wash buffer (PBS, 0.05% Tween-20,
pH 7.4) and were incubated with 0.5 ug/ml of the corresponding antibody for 1 h at room
temperature. After three washes, goat anti-rabbit HRP-linked antibody was incubated in
the wells at 1/15000 dilution for 40 min. Then, wells were washed three times and 100 ul
of substrate (TMB; Alpha Diagnostic, San Antonio, TX) was added to the wells for 15
min. The reaction was stopped with 100 ul of stop solution (Alpha Diagnostic, San
Antonio, TX) and read at 450 nm.

Epitope mapping of Anti-OPN-R and Anti-OPN-L

antibodies

To map the epitopes for Anti-OPN-R and Anti-OPN-L antibodies, the commercial
R&D Systems OPN antibody was used as the capture antibody. 10 ng/ml of milk OPN-R
and OPN-L were incubated in the antibody-coated wells.
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Peptides ALAYGLR,

SAAYGLR, SLGYGLR, SLAAGLR, SLAYALR, SLAYGAR, SLAYGLA, SLAYGLRNH2 , RLGYALS were used to epitope-map Anti-OPN-R antibodies, and SAVYGL,
SVAYGL, SWAGL, SVVYAL, SWYGA, SWYGL-NH 2 , RLGYALS were used for
Anti-OPN-L antibodies (Table I). Various molar excesses of peptides to antibodies
(ranging from 1:1 to 50:1, peptide to antibody ratio) were pre-incubated for 2 h at room
temperature, then were added to the wells and incubated for an additional hour. The
plates were then washed three times with wash buffer and 1/15000 dilution of goat antirabbit HRP-linked antibody was incubated in the wells for 40 min. Following three
washes the plates were developed as described in the previous section.

Detection ofOPN-FL, OPN-R and OPN-Lfrom RA, OA, andPsA synovial fluids
byELISA
Synovial joint fluids were thawed on ice and were incubated with 3 ug/ml of
HeteroBlock (Omega Biologicals, Bozeman, MT) to reduce the chance of cross-linking
between capture and detection antibodies by rheumatoid factor. Following a 10 min
centrifugation at 400 x g at 4°C (to clarify the samples), samples were diluted in R&D
Systems ELISA kit RD1-6 assay diluent. OPN-FL in synovial fluids was detected using
the R&D Systems commercial assay. OPN-R and OPN-L proteins were measured using
the sandwich ELISA systems described above. Due to the wide range of OPN levels
detected (ranging from 1-2 ng/ml to 50 ug/ml), median OPN levels are reported.
Statistical analysis were performed using the Wilcoxon Rank-Sum (Mann-Whitney) test
with/? values less than 0.05 being considered significant.
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Adhesion assay on preferential binding offibroblast-like

synoviocytes to OPN-R

Primary cultured fibroblast-like synoviocytes from RA joints, kindly provided by
Dr. Robinson, were maintained in Dulbecco's Modified Eagle's Medium (DMEM) with
10% FBS. Recombinant wild type and RGD-mutated human OPN-FL, OPN-R and
OPN-L (Table III), kindly provided by Dr. Leung, were coated onto 96-well micro black
fluorescent plates at 500 ng/ml in 0.1M NaHCCb, pH 8.5, and incubated for 2 h at room
temperature. Wells were washed with PBS and blocked using 2% BSA, 0.05% Tween
20, PBS pH 7.4 for 1 h. Fibroblast-like synoviocytes were labeled with CFDA cell tracer
dye (Invitrogen, Carlsbad, Ca) for 30 min at 37°C and washed twice with PBS. The
OPN-coated wells were washed with PBS and 5000 cells were added per well and
incubated for 1 h at 37°C. The wells were washed three times with PBS at room
temperature, and the plate was read at excitation wavelength of 488 nm and emission of
538 nm using Fluoroskan Ascent (Thermo Scientific, Waltham, MA).

Data were

recorded as relative fluorescence unit (RFU).
Table III. List of recombinant osteopontin proteins
Recombinant proteins

Sequence near thrombin cleavage site

OPN-FL Wild Type
OPN-R Wild Type
OPN-L Wild Type
RAA-OPN-FL
RAA-OPN-R
RAA-OPN-L

...153 VDTYDGRGDSVVYGLRSKSKKFR 175 ...
...153 VDTYDGRGDSVVYGLR 168
...153 VDTYDGRGDSVVYGL 167
...153 VDTYDGRAASWYGLRSKSKKFR 175 ...
...153 VDTYDGRAASVVYGLR 168
...153 VDTYDGRAASVVYGL 167

Sequence near the thrombin cleavage site is depicted. RGD has been mutated to RAA in some of
the proteins as indicated. Vector construction, expression and purification of the proteins were
performed by Dr. Timothy Myles in Dr. Leung's Laboratory and have been extensively described
in reference 14.
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Adhesion assay on preferential binding offibroblast-like
and SWYGLR

synoviocytes to RGDS

peptides

Primary cultured fibroblast-like synoviocytes were maintained as described in the
previous section.

0, 0.1, 1, 10, 100, 1000 uM RGDS, GRGES, SWYGLR, and

SWYGL peptides were coated onto 96-well micro black fluorescent plates in 0.1 M
NaHC0 3 , pH 8.5, and incubated for 2 h at RT. Wells were washed with PBS and
blocked using PBS, 2% BSA, pH 7.4 for 1 h. Fibroblast-like synoviocytes were labeled
with CFDA cell tracer dye (Invitrogen, Carlsbad, Ca) for 30 min at 37°C, and washed
twice with PBS. 5000 cells were added per well and incubated for lh at 37°C. The wells
were washed three times with PBS at RT and the plates were read at excitation
wavelength of 488 nm and emission of 538 nm.
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Results
Thrombin cleavage of milk osteopontin
To determine efficiency of thrombin cleavage of milk osteopontin, a time study
was conducted. lOug of OPN was treated with lOOnM of thrombin. At various time
points reaction was stopped by 200nM PPACK, and 500ng aliquots of OPN were
analyzed by SDS-PAGE (Fig. 3). Analysis of the SDS-PAGE revealed disappearance of
the full-length milk OPN (55KD) and appearance of OPN-R (30KD band) and the 25KD
C-terminal fragment with increasing time. It is interesting to note that after only 5
minutes of incubation with lOOnM thrombin the cleaved products are already visible.
The reaction seemed to have reached completion at 50 minutes. Therefore, to generate
OPN-R for ELISA calibration curves 1 h was chosen as the ideal incubation time with
lOOnM of thrombin.
FIGURE 3. Thrombin time-course of osteopontin cleavage
Purified milk osteopontin (lOug) was incubated with lOOnM of thrombin at 37°C and at
various time points the reaction was stopped by PPACK and 500ng of osteopontin (per
lane) was analyzed by SDS-PAGE.
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Specificity determination of antibodies Anti-OPN-R and Anti-OPN-L for OPN-R
and OPN-L respectively by Western blot
Specificity of antibodies, Anti-OPN-R (CA1999) and Anti-OPN-L (CA1998)
were tested by Western blot analysis. Anti-OPN (CA2001) recognized all forms of OPN
(Fig. 44).

Anti-OPN-L (CA1998) recognized human OPN-L with high degree of

specificity (Fig. 44 right panel).

The antibody raised against the mouse epitope

SLAYGLR for detection of OPN-R (CA1999 or Anti-OPN-R) was found to detect both
the human and mouse version of OPN-R specifically (Table II). The antibody raised
against the human version of the peptide SVVYGLR although recognized OPN-R was
not as reactive as the mouse antibody. Therefore, CA1999 was used for detection of
human OPN-R and CA1998 was used for detection of OPN-L for the remainder of the
study. The specificity of the two antibodies were further confirmed by using the cognate
and non-cognate peptides to block the antibody-antigen interactions. The peptide
SLAYGLR pre-incubated with Anti-OPN-R prior to probing the membrane, blocked
recognition of OPN-R by Anti-OPN-R (Fig. 48). However, pre-incubation of the AntiOPN-R with the non-cognate peptide at the same molar ratio did not block recognition of
OPN-R by the antibody. Similarly, the peptide SVVYGL pre-incubated with Anti-OPNL blocked recognition of OPN-L by Anti-OPN-L, but pre-incubation of the antibody with
the non-cognate SLAYGLR peptide had no effect on Anti-OPN-L recognition of OPN-L
(Fig. AC). In this study the focus was on CA1998 (Anti-OPN-L) for detection of human
OPN-L and CA1999 (Anti-OPN-R) for detection of human OPN-R.
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FIGURE 4. Specificity of antibodies against OPN determined by Western blot analysis.
A, Left panel: SDS-PAGE on different forms of OPN. Milk OPN was treated with
nothing (-), thrombin (Ila) or thrombin/CPB (Ila/CPB) to generate OPN-FL (60kD),
OPN-R (30KD) and OPN-L (30KD) respectively. A,Right Panel from left to right:
Western blot analysis of different forms of OPN with CA2001 (for recognition of all
forms of OPN), CA1999 (Anti-OPN-R), and CA1998 (Anti-OPN-L). B, Specificity of
Anti-OPN-R. From left to right: blot incubated with Anti-OPN-R only, 1:50 molar ratio
of Anti-OPN-R to cognate peptide, 1:50 molar ratio of Anti-OPN-R to non-cognate
peptide. C, Specificity of Anti-OPN-L. From left to right: blot incubated with Anti-OPNR, 1:50 molar ratio of Anti-OPN-L to cognate peptide and 1:50 molar ratio of Anti-OPNL to non-cognate peptide.
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Detection of human OPN by specific sandwich ELISA
The two antibodies, Anti-OPN-R and Anti-OPN-L, were used to develop ELISA
for detection of human OPN-R and OPN-L from biological fluids. The different forms of
milk OPN (OPN-FL, OPN-R, OPN-L) were used to construct calibration curves.
CA2001 antibody although detected the DTT, heat-denatured OPN in Western blot, it
was unable to recognize the native form of full-length OPN in the ELISA system.
Therefore, R&D Systems ELISA kit was used to measure the OPN-FL levels according
to manufacturer instructions. The R&D Systems OPN ELISA kit capture antibody was
also used for capture of OPN-R and OPN-L. The kit was very sensitive for detection of
OPN-FL, but not for OPN-R and OPN-L (Fig. 5A). Anti-OPN-R and Anti-OPN-L were
much more sensitive and specific for detection of the cleaved forms of OPN. Anti-OPNR antibodies detected OPN-R, but not OPN-FL or OPN-L (Fig. 5B). Similarly, AntiOPN-L antibodies reacted specifically with OPN-L, but not OPN-FL or OPN-R
(Fig. 5Q.

The ELISA detected as low as 0.6 ng/ml of OPN-R and OPN-L using the

antibodies. To ensure that presence of high level of full-length OPN does not affect the
detection efficiency of OPN-R and OPN-L, a 20-fold molar excess of intact full-length
OPN was incubated with either OPN-R or OPN-L in the wells (Fig. 6A&B). Such excess
did not affect the read-out of the ELISA, signifying that the OPN-R and OPN-L assays
are appropriate for measuring the cleaved forms of OPN from blood and other biological
fluids in presence of high levels of intact OPN.
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FIGURE 5. Development of specific sandwich ELISA for OPN-R and OPN-L
A, R&D Systems OPN kit is specific for OPN-FL, but not OPN-R and OPN-L. B,
Development of sandwich ELISA specific for OPN-R. C, Development of sandwich
ELISA specific for OPN-L.
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FIGURE 6. OPN-FL does not interfere with OPN-R and OPN-L in sandwich ELISA
A, OPN-FL does not interfere with OPN-R ELISA. 20 fold molar excess of OPN-FL
incubated with OPN-R at different concentrations were compared with OPN-R only
wells, at 20 fold molar excess. B, OPN-FL does not interfere with OPN-L ELISA. 20:1
ratio of OPN-FL to OPN-L vs. OPN-L only wells, showed non-interference of OPN-FL
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Epitope mapping ofAnti-OPN-R

and Anti-OPN-L

antibodies

To identify the exact epitopes of OPN-R and OPN-L recognized by Anti-OPN-R
and Anti-OPN-L antibodies respectively, a series of peptides were synthesized based on
the sequence of peptides used as immunogens for generation of the antibodies (Table II).
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The cognate peptide for Anti-OPN-R was the mouse sequence SLAYGLR, and
the peptide used as the immunogen for generation of Anti-OPN-L was SVVYGL. In
order to identify which amino acids from the peptides are important for interaction with
the respective antibodies, alanine was introduced in place of each of the amino acids in
the synthesized peptides (Table I). The peptides were used as competitive inhibitors of
the antibodies binding to OPN-R and OPN-L in the sandwich ELISA systems. The
competitive inhibition assay with all peptides were done with increasing molar ratio of
peptides to antibodies, but the dose dependent-curves are only depicted for the cognate
and the non-cognate peptides (Fig. 1A&.C). The rest of the peptide blocking experiments
are only shown at 50:1 molar ratio of peptides to antibodies for convenience
(Fig. 1B&D).
For Anti-OPN-R antibodies, pre-incubation of the antibodies with increasing
molar excess of the peptides SLAYGLR and SWYGLR inhibited the binding of the
antibodies to OPN-R in a dose-dependent manner (Fig. 1A). However, the peptides
SLAYGL and SVVYGL did not interfere with binding of Anti-OPN-R antibodies to
OPN-R coated plate, confirming the C-terminal arginine in the thrombin-cleaved OPN is
essential for recognition of OPN-R by Anti-OPN-R.

The peptides ALAYGLR,

SAAYGLR, SLGYGLR effectively inhibited the binding of Anti-OPN-R, indicating that
serine, leucine, and alanine residues of SLAYGLR are not essential for Anti-OPN-R
recognition (Fig. IB). On the other hand, substitution of alanine for tyrosine, second
leucine, arginine, and glycine

rendered the peptides SLAAGLR, SLAYGAR,

SLAYGLA, and to some degree SLAYALR ineffective in inhibiting the binding of Anti-
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OPN-R antibodies to OPN-R. This means tyrosine, second leucine, arginine, and to some
degree glycine in SLAYGLR are involved in defining the epitope for Anti-OPN-R. The
epitope YGLR is shared by both human and mouse version of thrombin-cleaved OPN,
which explains why Anti-OPN-R (raised against the mouse epitope SLAYGLR, and not
the human epitope SVVYGLR), effectively recognizes both human and mouse OPN-R.
In addition, substituting the C-terminal carboxyl group of arginine by an amide group
diminished inhibitive effect of the peptide, indicating that the carboxyl group is also
essential for recognition by Anti-OPN-R.
For Anti-OPN-L antibodies, the cognate peptide SWYGL effectively blocked
antibody binding in a dose-dependent manner while the peptide sequence SVVYGLR
was completely ineffective (Fig. 1C).

Furthermore, the blocking studies indicated

tyrosine, glycine, leucine, the C-terminal carboxyl group, and to a lesser extend the first
valine in the peptide sequence SWYGL are essential in defining the epitope for AntiOPN-L (Fig. ID).

The blocking studies showed Anti-OPN-R and Anti-OPN-L

essentially recognize three to four residues, with the C-terminal residues arginine or
leucine and their carboxylates being most important for recognition by the specific
antibodies.
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FIGURE 7. Epitope mapping of Anti-OPN-R and Anti-OPN-L antibodies by
competitive ELISA
A & B, Epitope mapping of Anti-OPN-R antibodies by various peptides. A, Anti-OPN-R
antibodies recongnition of OPN-R were blocked by pre-incubation of antibodies with
increasing concentrations of cognate peptides (SLAYGLR and SVVYGLR). B, AntiOPN-R inhibition by various peptides at 50:1 molar excess of peptides to antibodies
signifies the bold underlined epitopes in SLAYGLR are important for recognition of
OPN-R by Anti-OPN-R. C, Anti-OPN-L antibodies' recongnition of OPN-L were
blocked by pre-incubation of antibodies with increasing concentration of cognate peptide
(SVVYGL). D, Anti-OPN-L inhibition by various peptides at 50:1 molar excess of
peptides to antibodies signifies the bold underlined epitopes in SVVYGL are important
for recognition of OPN-L by Anti-OPN-L.

Molar Ratio Peptide to Afltt-OPN-L

^&^^^&A&&J*&-4r

22

Determination ofOPN-Fl, OPN-R and OPN-L levels from synovial fluids ofRA,
OA, andPsA patients by ELISA
Previous studies have reported increased OPN levels in synovial fluids from RA
patients (8, 10). To test whether cleaved forms of OPN are also detectable in the synovial
fluid samples of RA patients, ELISA systems were developed for detection of cleaved
forms of OPN. The commercial R&D Systems ELISA kit was used for detection of
OPN-FL. For comparison of RA synovial fluid OPN levels, synovial fluid samples from
OA and PsA were used since synovial fluid from healthy joints cannot be obtained. The
Wilcoxon rank sum test was used to compare the median values of each OPN form
between the three patient groups. In rheumatoid arthritis patients synovial fluids OPNFL (352.5 ng/ml) was significantly elevated compared to their normal plasma level (50
ng/ml), however, this level did not reach significance when compared to the OPN-FL
level from OA (157.9 ng/ml, p-value 0.142) and PsA (143.4 ng/ml, p value 0.074)
synovial fluids (Fig. &4).

On the other hand, OPN-R and OPN-L levels were

significantly higher in RA synovial fluids when compared to OA and PsA. The median
RA OPN-R level was 138.6 ng/ml compared to a 10.6 ng/ml for OA and 2.2 ng/ml for
PsA (p value < 0.001), and the median OPN-L level of RA was 205.3 ng/ml compared to
25.9 ng/ml for OA and undetectable for PsA (p value < 0.006) (Fig. 8A). There was a
wide range of full-length and cleaved OPN levels in the synovial fluids of RA patients
compared to OA and PsA, ranging from undetectable to more than 50 ug/ml. Such
heterogeneity in OPN levels may be due to differences in stage of the disease, the
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particular treatment in individual patients, or other factors. The median ratio of cleaved
OPN to total OPN in rheumatoid arthritis synovial fluid was 0.5, indicating that a
significant amount of OPN exists in its cleaved forms within the rheumatic joint space
compared to the OA and PsA (Fig. 85).
FIGURE 8. Comparison of OPN-FL, OPN-R and OPN-L from OA, PsA, and RA
synovial fluids by ELISA.
A, Comparison of OPN levels in Osteoarthritis (OA) n=18, psoriatic arthritis (PsA) n=10,
rheumatoid arthritis (RA) n=26. Bars indicate median values of each disease group. *p
value < 0.006 by Wilcoxon Ranked Sum test. B, Significantly higher cleaved OPNs
detected in RA patients' synovial fluids. The ratio of cleaved OPNs (OPN-R plus OPNL) to total OPN (sum of the three different OPN forms) for OA, PsA, and RA are
depicted. * p value < 0.003.
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Determination of preferential binding offibroblast-like

synoviocytes to OPN-R

To investigate the role of thrombin-cleaved OPN in RA, adhesion of arthritic
fibroblast-like synoviocytes to different forms of osteopontin was studied. Previously
described wild type and RGD-mutated recombinant OPN-FL, OPN-R, and OPN-L (14)
were coated onto a 96-well plate. In the RGD-mutated forms of OPN, the RGD site was
mutated into RAA in order to distinguish RGD-dependent adhesions (through integrins
such as avP3) from RGD-independent adhesions. A significant two-fold increase in FLS
adhesion was seen with wild type OPN-R compared to wild type OPN-FL and OPN-L,
suggesting the exposure of the cryptic integrin-binding motif SVVYGLR in OPN-R to be
the reason for the enhanced binding (Fig. 9A). However, in the case of both OPN-F1
(where the SVVYGLR is sterically-hindered) and OPN-L (where the C-terminal arginine
has been cleaved off by CPB) the enhanced binding of FLS to OPN is significantly
diminished. Lack of specific binding to RGD-mutated (RAA) versions of the three forms
of OPN in comparison with the wild type OPNs suggests that RGD is essential for the
initial binding of FLS to OPNs. In the absence of the RGD sequence, SVVYGLR alone
was unable to support binding to a4 integrin subunits (RAA-OPN-R), perhaps due to
lack of conformational integrity. The magnitude of cell binding was clearly enhanced
when both RGD and SVVYGLR were present.
To further investigate whether RGD is essential for adhesion of FLS, various
amounts of RGDS peptide (ranging from 0.1 to 1000 uM) were coated onto 96-well
plates and FLS adhesion to RGDS peptide-coated wells were compared to adhesion to
GRGES peptide (Fig. 92?). As expected, FLS adhered to RGDS peptide in a dose-
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dependent manner. Similarly, when SVVYGLR and SVVYGL peptides were coated
onto the wells, FLS adhered to SVVYGLR peptide, but not SVVYGL in a dosedependent manner (Fig. 9C).
FIGURE 9. Preferential adhesion of fibroblast-Like synoviocytes (FLS) to thrombincleaved OPN (OPN-R)
A, Fluorescently labeled fibroblast-like synoviocytes adhesion to WT OPN-F1, OPN-R,
OPN-L, RGD mutated OPNs (indicated as RAA-FL, RAA-R, and RAA-L), and BSA
coated wells. Data representative of four experiments with n = 8. B, Fluorescently
labeled FLS adhesion to RGDS (avP3 integrin binding site) coated wells in a dosedependent manner. C, FLS adhesion to SVVYGLR (oupi integrin binding site) coated
wells in a dose-dependent manner. B & C, Data representative of two experiments with
n=6.
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Discussion
The hypothesis that prompted this study was the premise that thrombin cleavage
of OPN plays a role in the pathophysiology of RA, and that cleavage of OPN-R by CPB
may down regulate the role OPN-R plays in rheumatoid arthritis. Recent studies have
reported increased OPN levels in the RA synovial fluids (9, 10). Ohshima et al. also
reported presence of cleaved forms of OPN in RA synovial fluids using an indirect
ELISA method (10). They compared binding of an antibody that recognizes both intact
and cleaved forms of OPN to one which recognizes intact OPN only, in order to deduce
the level of thrombin-cleaved OPN is high in RA compared to osteoarthritis. On the
contrary, the OPN-R and OPN-L ELISA described in this study directly detect the
thrombin-cleaved and the thrombin / CPB-cleaved osteopontin in biological fluids and
can distinguish these forms from the MMP3 and MMP7-cleaved products.
Extensive characterization of the two antibodies, Anti-OPN-R and Anti-OPN-L,
by Western blot (Fig. 4) and ELISA (Fig. 5 and Fig. 6) is indicative of the specificity of
the antibodies for their respective antigens. Epitope mapping of OPN-R antibodies
revealed that Anti-OPN-R, which was raised against SLAYGLR peptide, specifically
binds to the four amino acids YGLR. On the other hand, Anti-OPN-L raised against
SVVYGL recognizes the first valine and the YGL sequence. The fact that the C-terminal
residues N-terminal to the thrombin / CPB cleavage site, namely leucine (in the case of
Anti-OPN-L) and arginine (in the case of Anti-OPN-R) and their carboxyl groups are
essential for antibody recognition (Fig. 7), confirm that the antibodies would not
recognize MMP3 and MMP9-cleaved OPN. Since the two metalloproteinases are known
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to cleave after glycine within the SVVYGLR sequence, cleavage with these
metalloproteinases essentially destroys the Anti-OPN-R and Anti-OPN-L recognition
sites.

It should be noted, even though Anti-OPN-R and Anti-OPN-L specifically

recognize the thrombin-cleaved and thrombin / CPB-cleaved OPN, they cannot
distinguish whether these cleaved forms of OPN have been further cleaved by other
proteases.
Once specificity of the antibodies were determined, they were used to investigate
whether OPN-R and OPN-L could be detected from the RA synovial fluids. Synovial
fluid OPN has not been characterized, but it is known that the protein is highly modified
post-translationally.

Therefore, it could be speculated that the glycosylation and

phosphorylation patterns of OPN found in synovial fluid would be different from milk
OPN and could possibly contribute to differential affinities of the antibodies for the two
forms. Therefore, the initial attempt was to analyze the synovial fluid OPN by Western
blot. However, due to the presence of high concentrations of albumin, immunoglobulins
and rheumatoid factor in the synovial fluid samples which non-specifically reacted with
the antibodies, Western blot analysis of synovial fluid OPN failed. Therefore, sandwich
ELISA was used as the method of choice, to minimize non-specific interactions. In this
way only osteopontin would bind to the Anti-OPN capture antibody on the plate and all
else would be washed away, therefore, the chance of cross-reactivity with antibodies
were minimized. However, in a Western blot setting where whole synovial fluid is run on
a gel and all proteins are transferred onto a blot the chance of non-specific interactions
are considerably higher.
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Using the specific OPN-R and OPN-L ELISA, levels of both OPN-R and OPN-L
were found to be significantly elevated within the rheumatic joints compared to their
levels in OA and PsA joints, supporting the notion that thrombin cleavage of OPN and
the subsequent cleavage of OPN-R into OPN-L by CPB occur within the rheumatic
joints.
There was a wide range of full-length and cleaved OPN levels in the synovial
fluids of RA patients compared to OA and PsA, ranging from undetectable to more than
50 ug/ml (Fig. 8A). Such wide distribution of OPN level may be partly attributed to
stage of disease, its severity, and the particular treatment regimen at time of synovial
fluid collection. Therefore, further studies of the inflammatory state of the patients are
necessary to understand the heterogeneity of OPN levels found in RA.
Contrary to previous published results (10), in this study the median OPN-FL
level of RA synovial fluids was not significantly higher compared to OA and PsA
(Fig. 8A). This finding may be partly explained by the small sample size, or by variations
in the inflammatory stage of disease and treatment regimens of individual patients at time
of fluid collection.
The ratio of cleaved OPNs (OPN-R and OPN-L) to OPN-FL in RA synovial fluid
samples had a median value of 0.5, suggesting that almost half of the OPN within the
rheumatic joint space has been cleaved into OPN-R and OPN-L (Fig. 8B). On the
contrary, the ratio of cleaved OPNs to OPN-FL in OA and PsA was significantly lower.
This finding is suggestive that the cleaved forms of OPN may play important roles in the
pathogenesis of RA, but not OA and PsA.
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Once it was established that cleaved OPNs are present at high levels in at least a
subset of RA synovial fluids, the biological relevance of this finding was explored using
cells from RA joints. The primary fibroblast-like synoviocytes (FLS) within the joint
space express a4 (CD49d) on their surface (23). On the other hand, thrombin-exposed Cterminal sequence SVVYGLR of OPN-R binds to the a4 subunit of a4(31 (18).
Furthermore, data on integrin profile of fibroblast-like synoviocytes showed there is a 3-4
fold increased expression of cc4 in rheumatoid arthritic synovium compared to normal
synovium (23).

This information along with the finding that FLS binds OPN-R

preferentially when compared to OPN-FL and the doubly-cleaved OPN-L (Fig. 9A),
suggest thrombin-cleaved form of osteopontin may be biologically active in rheumatoid
arthritis. While OPN-R was able to support substantial cell binding, adhesion to OPN-L
was reduced to levels seen with OPN-FL, suggesting that in vivo CPB conversion of
OPN-R into OPN-L, may possibly serve as a regulator of integrin-mediated cell adhesion
to OPN-R. Although the present study is suggestive that OPN-R has a possible role in
the pathogenesis of RA, further studies are needed to investigate the specific nature of the
interaction of OPN-R with the fibroblast-like synoviocytes within the joint space and the
role OPN-R may play in the progression of rheumatoid arthritis. In addition, the cleaved
OPN ELISA systems developed for this study may serve as an effective tool for studying
thrombin-cleaved OPN and thrombin / CPB-cleaved OPN levels in
inflammatory conditions.
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